These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39523878)
1. Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial. Jin P; Liu Q; Chen W; Guo X; Jiang H; Zhang R; Ding M; Zhang K; Cao Z; He J; Jia S; Wei M; Hu Y; Cui L; Wang J; Li Z; Zhang X; Xia X; Wu Y; Zhou L; Zhu Y; Gao C; Zhang T; Zhu F; Zeng G; Zhu L; Li J Expert Rev Vaccines; 2024; 23(1):1041-1051. PubMed ID: 39523878 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G; Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R; Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389 [TBL] [Abstract][Full Text] [Related]
6. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial. Naficy A; Kuxhausen A; Seifert H; Hastie A; Leav B; Miller J; Anteyi K; Mwakingwe-Omari A Hum Vaccin Immunother; 2024 Dec; 20(1):2327736. PubMed ID: 38513689 [TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study. Maddeppungeng M; Nurdin A; Nency YM; Sekartini R; Medise BE; Soedjatmiko S; Massi MN; Darma S; Darussalam AHE; Ramadhani N; Hidayah N; Chalid MT; Ramadany S; Wahyuni S; Djaharuddin I; Santoso A; Fikri B; Alimuddin S; Pelupessy NM; Masadah R; Putri AZ; Setyaningsih L; Yani FF; Anggrainy F; Deza PA; Maharani N; Mahati E; Hapsari R; Farhanah N; Pramudo SG; Tri Anantyo D Hum Vaccin Immunother; 2024 Dec; 20(1):2429231. PubMed ID: 39632708 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. Madhi SA; Baillie V; Cutland CL; Voysey M; Koen AL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Kwatra G; Ahmed K; Aley P; Bhikha S; Bhiman JN; Bhorat AE; du Plessis J; Esmail A; Groenewald M; Horne E; Hwa SH; Jose A; Lambe T; Laubscher M; Malahleha M; Masenya M; Masilela M; McKenzie S; Molapo K; Moultrie A; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Rossouw L; Taoushanis C; Tegally H; Thombrayil A; van Eck S; Wibmer CK; Durham NM; Kelly EJ; Villafana TL; Gilbert S; Pollard AJ; de Oliveira T; Moore PL; Sigal A; Izu A; ; N Engl J Med; 2021 May; 384(20):1885-1898. PubMed ID: 33725432 [TBL] [Abstract][Full Text] [Related]
9. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N; Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588 [TBL] [Abstract][Full Text] [Related]
11. Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China. Li J; Xu J; Liu Y; Chen L; Yu L; Xiao X; Wang Q Hum Vaccin Immunother; 2024 Dec; 20(1):2389602. PubMed ID: 39171541 [TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10-60 years in China. Liang Z; Chen X; Xing B; Hu X; Liu M; Zhang X; Shen Y; Wang Y; Chen Y; Lv H; Mao Y Front Immunol; 2024; 15():1444686. PubMed ID: 39575262 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE; Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490 [TBL] [Abstract][Full Text] [Related]
15. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. Walsh MR; Alam MS; Pierce KK; Carmolli M; Alam M; Dickson DM; Bak DM; Afreen S; Nazib F; Golam K; Qadri F; Diehl SA; Durbin AP; Whitehead SS; Haque R; Kirkpatrick BD Lancet Infect Dis; 2024 Feb; 24(2):150-160. PubMed ID: 37776876 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial. Modjarrad K; Scott PT; McCauley M; Ober-Shepherd B; Sondergaard E; Amare MF; Parikh AP; Omar B; Minutello AM; Adhikarla H; Wu Y; P AR; Delore V; Mantel N; Morrison MN; Kourbanova KS; Martinez ME; Guzman I; Greenleaf ME; Darden JM; Koren MA; Hamer MJ; Lee CE; Hutter JN; Peel SA; Robb ML; Vangelisti M; Feroldi E Lancet Infect Dis; 2024 Dec; 24(12):1393-1402. PubMed ID: 39153488 [TBL] [Abstract][Full Text] [Related]
17. A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity. Klinkardt U; Schunk M; Ervin J; Schindler C; Sugimoto D; Rankin B; Amann R; Monti M; Kutschenko A; Schumacher C; Huber K; Zeder A; Heikkila N; Didierlaurent AM; Schwarz SE; Derouazi M Hum Vaccin Immunother; 2024 Dec; 20(1):2410574. PubMed ID: 39397784 [TBL] [Abstract][Full Text] [Related]
18. Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India. Tripathy AS; Singh D; Trimbake D; Salwe S; Tripathy S; Kakrani A; Jali P; Chavan H; Yadav P; Sahay R; Sarje P; Babar P; Shete A; Nandapurkar A; Kulkarni M Hum Vaccin Immunother; 2024 Dec; 20(1):2410579. PubMed ID: 39434214 [TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized, parallel, active controlled, phase III Indian study of immunogenicity and safety of two inactivated influenza vaccines - Vaxiflu-4 and Fluarix tetra in children aged 6 months to 35 months. Kothari K; Shah S; Gill VK; Ray RK; Kumar NR; Sanmukhani J; Daultani P; Mittal R; Dutta T; Mahajan M; Desai S Hum Vaccin Immunother; 2024 Dec; 20(1):2416329. PubMed ID: 39445787 [TBL] [Abstract][Full Text] [Related]
20. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome. Nouwen AEM; Zaeck LM; Schappin R; Geers D; Gommers L; Bogers S; Dik WA; Pasmans SGMA; GeurtsvanKessel CH; de Vries RD; Dalm VASH J Clin Immunol; 2024 Oct; 45(1):36. PubMed ID: 39476295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]